"Pharmaceutical headlines" set to promote three years of local leading pharmaceutical companies in what kind of bureau?

(2020/09/17) Mercer East's partnership with Seattle Genetics will further expand the Keytruda franchise; East Sunshine Pharmaceuticals will have nine heavyweight varieties and 18 varieties will be awarded the first Class 1 new drug; and two consecutive ADC heavyweight deals Gilead and Mercedon have different options behind... (Click on the title to get the original article) The collaboration between Mercer East and Seattle Genetics will further expand the Keytruda franchise, days after Mercer east announced a $1.6 billion partnership to use Keytruda with Seattle Genetics' research drug Ladiratuzumab Vedotin (LVNBC) for the treatment of metastasis triple negative breast cancer.
, the deal could give Mercedon a foothold in the hot ADC sector and at least cement Keytruda's position in the highly collaborative ADC portfolio,
SVB Leerink analyst Daina Graybosch wrote in a letter to investors on Tuesday.
: Opdivo-Adcetris portfolio is the most promising.
"Mi Net" East Sunshine Drug took 9 heavy-weight varieties 18 varieties over-evaluation The first class 1 new drug will be born recently, The East Sunshine drug product line came with good news, O nitrogen flat tablets were approved and treated as over-evaluation, 2 new drugs recombinant anti-VEGF humanized monoclonal antibody injection was approved clinical, 1 new drug HEC95468 clinical application was accepted ... So far this year, 9 varieties (17 product regulations) have been approved for market, of which 5 varieties are diabetes drugs;
currently 18 varieties of East Sunshine Medicine have been evaluated (10 for the first).
: 26 new products on the way.
is behind the two consecutive ADC heavyweight deals between Gilead and Mercedon? Two big ADC drug deals in a row have refocused attention on antibody-coupled drugs: on September 13th Gilead announced that it would buy Immunomedics for $88 a share in cash, a deal that is expected to close in the fourth quarter of this year.
September 14, MercaTon announced two partnership agreements with Seattle Genetics in a deal worth $4.5 billion.
: ADC drugs are entering a period of rapid development.
"E drug manager" collection policy to promote three years of multi-differentiation shows that the local leading pharmaceutical companies in the third batch of national drug centralized procurement in August just ended, 194 pharmaceutical companies submitted a total of 354 varieties of quotations, the final 123 enterprises 191 varieties of winning the bid.
the 191 varieties shortlisted have achieved varying degrees of price reduction.
Through several rounds of national harvesting, we can observe that it is becoming more obvious that, unlike multinational pharmaceutical companies, local pharmaceutical companies participate in the collection of more positive attitude, in line with policies, active price reduction, and strive for the election.
For example, Qilu Pharmaceuticals, which won the crown in the third batch, was selected in 8 varieties, ranking first, with a winning rate of 100%, and 7 of them were selected in first place.
: the local leading enterprises selected frequently in the collection are the leading players in the transformation of China's pharmaceutical industry.
.